NCT04300556 2026-03-13A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesEisai Inc.Phase 1/2 Recruiting182 enrolled
NCT06253494 2026-03-03Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerNational Institutes of Health Clinical Center (CC)Phase 1/2 Recruiting60 enrolled
NCT04008797 2026-02-27A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorEisai Inc.Phase 1/2 Active not recruiting301 enrolled
NCT05620134 2024-10-15Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerSalubris Biotherapeutics IncPhase 1/2 Active not recruiting263 enrolled
NCT01133756 2023-06-22E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125Eisai Inc.Phase 1/2 Terminated7 enrolled 6 charts